Kiran Nistala, MBBS, PhD, serves as Chief Medical Officer and Head of Development at Zura. He is an experienced physician and immunologist with nearly two decades of expertise in translational medicine and the strategic design of clinical trials, spanning a diverse spectrum of medical disorders.
Prior to joining Zura, Dr. Nistala served as Vice President of late-stage clinical development in Immunology at AstraZeneca, where he was instrumental in their therapeutic build in autoimmune disease. His primary focus was on Immunology programs aimed at addressing conditions such as lupus, myositis, scleroderma, and eosinophilic disorders.
Prior to his tenure at AstraZeneca, Dr. Nistala held a series of increasingly senior positions at GlaxoSmithKline, where his contributions ranged from pivotal roles in research strategy, immune safety governance boards, the design of clinical protocols, and championing translational medicine initiatives. In addition to his corporate roles, Dr. Nistala served as an Honorary Consultant in Pediatric Rheumatology at Great Ormond Street Hospital for Children NHS Foundation Trust in the United Kingdom, demonstrating his commitment to both academic and clinical excellence.
Dr. Nistala earned a bachelor’s degree in Psychology from the University of Cambridge, a combined MBBS and PhD in Immunology from University College London, and completed advanced scientific training with a prestigious Clinician Scientist Fellowship from the Wellcome Trust.
What is Kiran Nistala's net worth?
The estimated net worth of Kiran Nistala is at least $19.52 thousand as of April 22nd, 2024. Nistala owns 3,195 shares of Zura Bio stock worth more than $19,521 as of April 1st. This net worth approximation does not reflect any other investments that Nistala may own. Learn More about Kiran Nistala's net worth.
How do I contact Kiran Nistala?
Has Kiran Nistala been buying or selling shares of Zura Bio?
Kiran Nistala has not been actively trading shares of Zura Bio during the past quarter. Most recently, on Monday, April 22nd, Kiran Nistala bought 3,195 shares of Zura Bio stock. The stock was acquired at an average cost of $3.13 per share, with a total value of $10,000.35. Following the completion of the transaction, the executive vice president now directly owns 3,195 shares of the company's stock, valued at $10,000.35. Learn More on Kiran Nistala's trading history.
Who are Zura Bio's active insiders?
Are insiders buying or selling shares of Zura Bio?
During the last year, Zura Bio insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $12,500,000.00. The most recent insider tranaction occured on February, 26th when Major Shareholder Ai Biotechnology Llc bought 2,000,000 shares worth more than $12,500,000.00. Insiders at Zura Bio own 22.1% of the company.
Learn More about insider trades at Zura Bio. Information on this page was last updated on 2/26/2026.
